Lenalidomide in the treatment of chronic lymphocytic leukemia

Bibliography

• Corral LG, Haslett PA, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E, Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7
   PubMed Web of Science ®Google Scholar
• Chronic Lymphocytic Leukemia. National Cancer Institute. SEER Stat Fact Sheets. Bethesda, MD: National Cancer Institute 2009. Available from: http://seer.cancer.gov/statfacts/html/clyl.html. [Last accessed 13 December 2010]
   Google Scholar
• Catovsky D, Foa R. The lymphoid leukaemias. Butterworths, London; 1990
   Google Scholar
• Mauro FR, Foa R, Giannarelli D, Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448-54
   PubMed Web of Science ®Google Scholar
• Binet JL, Lepoprier M, Dighiero G, A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855-64
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7
   PubMed Web of Science ®Google Scholar
• Chevallier P, Penther D, Avet-Loiseau H, CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116:142-5
   PubMed Web of Science ®Google Scholar
• D'Arena G, Musto P, Cascavilla N, CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42:109-14
   PubMed Web of Science ®Google Scholar
• Ghia P, Guida G, Stella S, The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-9
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do KA, CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-6
   PubMed Web of Science ®Google Scholar
• Gentile M, Mauro FR, Calabrese E, The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549-57
   PubMed Web of Science ®Google Scholar
• Morabito F, Cutrona G, Gentile M, Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009;146:44-53
   PubMed Web of Science ®Google Scholar
• Durig J, Nuckel H, Cremer M, ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17:2426-34
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Jain S, Keating MJ, Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-30
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54
   PubMed Web of Science ®Google Scholar
• Hultdin M, Rosenquist R, Thunberg U, Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003;88:593-8
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-4
   PubMed Web of Science ®Google Scholar
• Gentile M, Cutrona G, Neri A, Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009;94:887-8
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-75
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-16
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-22
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-57
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. ASH Annual Meeting Abstracts. Blood 2009;114:535
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
   PubMed Web of Science ®Google Scholar
• Bergmann MA, Goebeler ME, Herold M, Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-64
   PubMed Web of Science ®Google Scholar
• Thornton PD, Matutes E, Bosanquet AG, High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-65
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196-203
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 2008;111:1094-100
   PubMed Web of Science ®Google Scholar
• Lenalidomide prescribing information. Summit, NJ: Celgene corporation, 2010. Available from: http://www.revlimid.com/pdf/REVLIMID_PI.pdf [Last accesssed 13 December 2010]
   Google Scholar
• Wu A, Scheffler MR. Multi-dose phamacokinetics and safety of CC-5013 in 15 multiple myeloma patients. J Clin Oncol 2004;22:141s
   Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22
   PubMed Web of Science ®Google Scholar
• Muller GW, Chen R, Huang SY, Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9:1625-30
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, Manshouri T, The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100:1215-19
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266-73
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PAJ, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61
   PubMed Web of Science ®Google Scholar
• Diederichsen ACP, Zeuthen J, Christensen PB, Kristensen T. Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer 1999;35:721-6
   PubMed Web of Science ®Google Scholar
• Ichihara F, Kono K, Takahashi A, Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8
   PubMed Web of Science ®Google Scholar
• Motta M, Rassenti L, Shelvin BJ, Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1788-93
   PubMed Web of Science ®Google Scholar
• Galustian C, Klaschka DC, Meyer B, Lenalidomide (Revlimid(R), CC-5013) and ActimidTM (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: implications for anti-tumor activity in vivo. AACR Meeting Abstracts; 2006. p. 1147
   Google Scholar
• Galustian C, Meyer B, Labarthe MC, The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37
   PubMed Web of Science ®Google Scholar
• Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001;28:602-6
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650-7
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, Molecular mechanisms where by immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203
   PubMed Web of Science ®Google Scholar
• Bartlett JB. Lenalidomide enhances tumor killing in vitro during ADCC mediated by trastuzumab, cetuximab, and rituximab. ASCO Meeting Abstracts. J Clin Oncol 2007;25:18S
   Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:2005-10
   Web of Science ®Google Scholar
• Idler I, Giannopoulos K, Zenz T, Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148:948-50
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50
   PubMed Web of Science ®Google Scholar
• James DF, Betty MR, Mosadeghi R, Kipps TJ. Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro. ASH Annual Meeting Abstracts. Blood 2007;110:3116
   Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Immunomodulatory drug CC-5013 or CC- 4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984-92
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45
   PubMed Web of Science ®Google Scholar
• Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-19
   PubMed Web of Science ®Google Scholar
• Zhang L-H, Schafer PH, Muller G, Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression. ASH Annual Meeting Abstracts. Blood 2008;112:2612
   Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-55
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A. Pro-apoptotic effect of lenalidomide in patients with chronic lymphocytic leukemia is possibly mediated through interruption of phosphatidylinositol pathway. ASH Annual Meeting Abstracts. Blood 2006;108:2102
   Web of Science ®Google Scholar
• Andritsos L, Johnson AJ, Lozanski G, Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-25
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180-9
   PubMed Web of Science ®Google Scholar
• Gaidarova S, Li JW, Corral LG, Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases. ASH Annual Meeting Abstracts. Blood 2009;114:3441
   Web of Science ®Google Scholar
• Lapalombella R, Gowda A, Joshi T, The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848-55
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Andritsos L, Liu Q, Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase dependent pathway. Blood 2010;115:2619-29
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Czuczman MS, Padmanabhan S, Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts. Blood 2007;110:3108
   Web of Science ®Google Scholar
• Sher T, Miller KC, Lawrence D, Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-8
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:5404-9
   PubMed Web of Science ®Google Scholar
• Moutouh-de Parseval LA, Weiss L, DeLap RJ, Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047
   PubMed Web of Science ®Google Scholar
• Maddocks K, Lapalombella R, Blum KA, Preliminary results of a Phase I study of lenalidomide in relapsed chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2009;114:3446
   Web of Science ®Google Scholar
• Wendtner CM, Mahadevan D, Stilgenbauer S, Preliminary results of a phase 1/2, multi-center, open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2008;112:2104
   Web of Science ®Google Scholar
• Aue G, Soto S, Valdez J, A phase II trial of pulse dosing lenalidomide: 3 weeks on 3 weeks off in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH Annual Meeting Abstracts. Blood 2009;114:3427
   Web of Science ®Google Scholar
• Chen CI, Paul H, Xu W, Safety and efficacy of slow dose escalation of lenalidomide for frontline treatment in chronic lymphocytic leukemia (CLL) – results of a phase II study. Haematologica 2009;94:S93
   Google Scholar
• Badoux XC, Wierda WG, O'Brien SM, Experience with lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. Haematologica 2009;94:S93
   Google Scholar
• Badoux XC, Reuben J, Lee B, Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lymphocytic leukemia. Haematologica 2009;94:S94
   PubMed Web of Science ®Google Scholar
• Guegan JP, Quillet-Mary A, Laurent G, Chronic lymphocytic leukemia/nurse-like cells interactions: release of soluble factor(s) that inhibit rituximab-dependent normal B cell depletion, and reversion by lenalidomide. Haematologica 2009;94:S28
   Google Scholar
• Brown JR, Abramson JS, Hochberg EP, A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010;24:1972-5
   PubMed Web of Science ®Google Scholar
• Brown JR, Abramson JS, Hochberg EP, A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Haematologica 2009;94:S86
   Google Scholar
• Egle A, Steurer M, Melchardt T, The REVLIRIT CLL5 AGMT study – a phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated CLL: results of a planned interim analysis. ASH Annual Meeting Abstracts. Blood 2009;114:3453
   Web of Science ®Google Scholar
• Ferrajoli A, Badoux XC, O'Brien S, Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2009;114:206
   Web of Science ®Google Scholar
• Veliz M, Santana R, Lancet JE, Phase II study of lenalidomide in combination with rituximab for patients with CD5+/CD20+ hematologic malignancies who relapse or progress after rituximab. Interim analysis. ASH Annual Meeting Abstracts. Blood 2009;114:2376
   Web of Science ®Google Scholar
• Sher T, Miller K, Patel M, Lenalidomide associated tumor flare reaction correlates with clinical response in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) [abstract 0928]. Haematologica 2009;94(Suppl 2):373
   Google Scholar
• Aue G, Njuguna N, Tian X, Lenalidomide induced cytokine release syndrome in chronic lymphocytic leukemia (CLL): clinical and laboratory correlates of immune activation. ASH Annual Meeting Abstracts. Blood 2008;112:2099
   Web of Science ®Google Scholar
• James D, Avery ED, Zhang L, Lenalidomide administered for the initial treatment of CLL patients - in vivo modulation of the leukemia cell surface phenotype and association with tumor flare reaction (TFR). ASH Annual Meeting Abstracts. Blood 2009;114:3440
   Web of Science ®Google Scholar
• Aue G, Lozier JN, Cullinane AM, Increased incidence of thrombosis with lenalidomide in chronic lymphocytic leukemia: effect of lenalidomide on inflammation, endothelial cell damage and coagulation. ASH Annual Meeting Abstracts. Blood 2009;114:455
   Web of Science ®Google Scholar
• Miller KC, Depaolo D, Padmanabhan S, Prophylaxis of venous thromboembolism using weight-adjusted low-dose warfarin sodium in chronic lymphocytic leukemia (CLL) patients treated with immunomodulatory drugs (IMiDs). Leuk Lymphoma 2007;48(Suppl 1):131
   Google Scholar